Table 3.
Results of in vitro synergy studies.
| strain | MIC (μg/mL)a | ΣFICd | |||||
|---|---|---|---|---|---|---|---|
|
|
|
||||||
| VAN | DSF | 1j | VANb/DSFc | VANb/1j | VANb/DSFc | VANb/1jc | |
| MRSA COL | 2 | 8 | 2 | 1/1 | 1/0.25 | 0.63 (+) | 0.75 (+) |
| VISA AR-217 | 4 | 4 | 0.5 | 2/1 | 0.5/0.25 | 0.75 (+) | 0.56 (+) |
| VRSA HIP14300 | >128 | 16 | 2 | 8/2 | 1/1 | <0.16 (++) | 0.5 (++) |
| VISE NRS53 | 8 | 4 | 2 | 4/2 | 2/1 | 1 (+) | 0.75 (+) |
a
vancomycin: VAN; disulfiram: DSF
b
lowest MIC of VAN in combination with DSF or 1j
c
lowest MIC of DSF or 1j in combination with VAN
d
lowest ΣFIC measurement; synergy (++) ≤ 0.5; additive (+) 0.5 < to ≤ 1; indifferent (±) 1< to ≤ 4; antagonism (−) > 4 [12]